Literature DB >> 27446345

Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease.

Yudan Wei1, Jing Lin2, Fan Yang3, Xiujiang Li4, Yue Hou1, Ronghua Lu5, Xiaonv Shi1, Zhi Liu1, Yujun Du1.   

Abstract

Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD), and its development and progression are affected by various factors. The aim of the present study was to identify the risk factors for SHPT in patients with CKD. A retrospective study was performed in 498 patients (305 males and 193 females) with CKD, observed in the The First Hospital of Jilin University between January 2008 and December 2012. The demographic, clinical and laboratory data were collected. Patients were divided into the SHPT group (n=424) with elevated serum parathyroid hormone (PTH) expression levels and the control group (n=74) with normal serum PTH expression levels. Univariate and multivariate regression analyses were employed to explore the risk factors for SHPT. Serum PTH expression levels in women with CKD were significantly higher than in men (P=0.047). Serum PTH expression levels were positively correlated with the expression levels of serum creatinine (P<0.01), phosphorus (P<0.01), C-reactive protein (P<0.05), triglyceride (P<0.05), cholesterol (P<0.05) and low-density lipoprotein cholesterol (P<0.05), but were negatively correlated with the expression levels of hemoglobin (P<0.05), calcium (P<0.01) and CO2 combining power (P<0.01) in patients with CKD. Multivariate analysis showed that the serum expression levels of creatinine [µmol/l; odds radio (OR), 1.003; 95% confidence interval (CI), 1.002-1.004; P=0.001] and phosphorus (mmol/l; OR, 2.19; 95% CI, 1.254-3.826; P=0.006) in patients with CKD significantly influenced serum PTH expression levels. The SHPT risk factors include female gender, low calcium, high phosphorus, acidosis, anemia, hypertension, hyperlipidemia and micro-inflammation, with blood phosphorus and creatinine being independent risk factors.

Entities:  

Keywords:  chronic kidney disease; creatinine; phosphorus; risk factor; secondary hyperparathyroidism

Year:  2016        PMID: 27446345      PMCID: PMC4950648          DOI: 10.3892/etm.2016.3438

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  46 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?

Authors:  Jeffrey L Anderson; Ryan C Vanwoerkom; Benjamin D Horne; Tami L Bair; Heidi T May; Donald L Lappé; Joseph B Muhlestein
Journal:  Am Heart J       Date:  2011-08       Impact factor: 4.749

3.  [Chronic microinflammation and endothelial damage in uremia].

Authors:  R Ojeda; P A Aljama
Journal:  Nefrologia       Date:  2008       Impact factor: 2.033

Review 4.  Oxidative stress in hemodialysis patients: is NADPH oxidase complex the culprit?

Authors:  Marion Morena; Jean-Paul Cristol; Lynne Senécal; Helene Leray-Moragues; Detlef Krieter; Bernard Canaud
Journal:  Kidney Int Suppl       Date:  2002-05       Impact factor: 10.545

5.  Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

Authors:  Sharon M Moe; Glenn M Chertow; Jack W Coburn; L Darryl Quarles; William G Goodman; Geoffrey A Block; Tilman B Drüeke; John Cunningham; Donald J Sherrard; Laura C McCary; Kurt A Olson; Stewart A Turner; Kevin J Martin
Journal:  Kidney Int       Date:  2005-02       Impact factor: 10.612

6.  The roles of the skeleton and phosphorus in the CKD mineral bone disorder.

Authors:  Keith A Hruska; Suresh Mathew
Journal:  Adv Chronic Kidney Dis       Date:  2011-03       Impact factor: 3.620

7.  Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.

Authors:  Kathryn E Ferrier; Michael H Muhlmann; Jean Philippe Baguet; James D Cameron; Garry L Jennings; Anthony M Dart; Bronwyn A Kingwell
Journal:  J Am Coll Cardiol       Date:  2002-03-20       Impact factor: 24.094

Review 8.  Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics.

Authors:  William G Goodman; L D Quarles
Journal:  Kidney Int       Date:  2007-06-13       Impact factor: 10.612

Review 9.  Anemia as a risk factor for chronic kidney disease.

Authors:  K Iseki; K Kohagura
Journal:  Kidney Int Suppl       Date:  2007-11       Impact factor: 10.545

10.  Exploring inflammation in hemodialysis patients: persistent and superimposed inflammation. A longitudinal study.

Authors:  George Tsirpanlis; Pantelis Bagos; Dimitris Ioannou; Aliki Bleta; Ioanna Marinou; Antonis Lagouranis; Stylianos Chatzipanagiotou; Chrysoula Nicolaou
Journal:  Kidney Blood Press Res       Date:  2003-12-23       Impact factor: 2.687

View more
  2 in total

1.  Evaluation of renal osteodystrophy in the dental clinic by assessment of mandibular and phalangeal cortical indices.

Authors:  Bruna Corrêa Massahud; João César Guimarães Henriques; Reinhilde Jacobs; Rafaela Rangel Rosa; Caio Vinícius Bardi Matai
Journal:  Oral Radiol       Date:  2017-09-04       Impact factor: 1.852

2.  Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease.

Authors:  Yang Xu; Marie Evans; Marco Soro; Peter Barany; Juan Jesus Carrero
Journal:  Clin Kidney J       Date:  2021-01-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.